Lupin gets green CHMP opinion for biosimilar RanibizumabLupin gets green CHMP opinion for biosimilar Ranibizumab

Introduction

Leading global pharmaceutical company received a positive CHMP opinion for its biosimilar ranibizumab, Ranluspec™, targeting multiple retinal conditions, with commercialization planned across the European Union pending regulatory approval.

Also Read: Vedanta gets NCLT approval for demerger, shares rise 2%

Share price movement of Lupin

On December 17, 2025, Lupin Ltd opened at ₹2,090.75, up 0.05% from its previous close of ₹2,089.65. The stock reached a high of ₹2,127.40 (1.81%) and a low of ₹2,090.75. By 2:41 PM, it traded at ₹2,106.10, a 0.79% increase, with a market cap of ₹96,206.40 crore.

Lupin Gets Positive CHMP Opinion

Lupin Limited announced a positive CHMP opinion for its biosimilar ranibizumab, Ranluspec™. The recommendation covers both vial and pre-filled syringe presentations for multiple retinal conditions.

Ranibizumab targets VEGF-A and treats wet AMD, macular edema from RVO, DME, PDR, and CNV. Approval is based on analytical similarity and a 600-patient global phase III clinical trial.

The CHMP opinion will be reviewed by the European Commission for centralized EU marketing authorization. Sandoz Group AG will commercialize Ranluspec™, with France also involving Biogaran.

Stock performance of Lupin for Period of 1 week, 6 months, and 1 year

Lupin Ltd delivered a 1.71% return over the past week. It gained 7.32% in the past six months and rose 2.12% over the past year.

Also Read: Ahluwalia Contracts jumps 5% after ₹888.38 Cr construction order from Bihar tourism

Shareholding pattern of Lupin

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	47%	47%	47%
FII	20.50%	21.30%	21.50%
DII	26.60%	25.60%	25.40%
Public	6.10%	6.30%	6.20%

About Lupin

Lupin Ltd (NSE: LUPIN) is a global pharmaceutical company headquartered in Mumbai, specializing in branded and generic formulations, complex generics, biotechnology products, and APIs, with operations in over 100 markets worldwide.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs